Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bonella, Francesco
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Active, not recruiting	3	160	Europe, Canada, Japan, US, RoW	Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo	Savara Inc., Savara ApS,	Autoimmune Pulmonary Alveolar Proteinosis	11/23	11/24
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	Completed	2	81	Europe, Canada, US, RoW	Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo	CSL Behring	Idiopathic Pulmonary Fibrosis	01/24	01/24
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	2	150	Europe, Canada, US, RoW	GSK3915393, Placebo	GlaxoSmithKline	Idiopathic Pulmonary Fibrosis	03/26	03/26